Renovaro Biosciences (RENB) 10-Q 14 Feb 22 2022 Q2 Quarterly report Financial data

Cover

Cover - shares	6 Months Ended
	Dec. 31, 2021	Feb. 14, 2022
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Dec. 31, 2021
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2022
Current Fiscal Year End Date	--06-30
Entity File Number	001-38758
Entity Registrant Name	Enochian Biosciences Inc.
Entity Central Index Key	0001527728
Entity Tax Identification Number	45-2259340
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	2080 Century Park East
Entity Address, Address Line Two	Suite 906
Entity Address, City or Town	Los Angeles
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	90067
City Area Code	(305)
Local Phone Number	918-1980
Title of 12(b) Security	Common Stock, par value $0.0001 per share
Trading Symbol	ENOB
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		52,633,267

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($)	Dec. 31, 2021	Jun. 30, 2021
CURRENT ASSETS:
Cash	$ 13,707,907	$ 20,664,410
Other receivables		1,640
Prepaid expenses	910,637	232,943
Total Current Assets	14,618,544	20,898,993
Property and equipment, net	668,723	719,364
OTHER ASSETS:
Definite life intangible assets, net	55,413	65,906
Indefinite life intangible assets	154,824,000	154,824,000
Goodwill	11,640,000	11,640,000
Deposits and other assets	31,494	20,984
Operating lease rights-of-use assets	1,297,964	1,435,978
Total Other Assets	167,848,871	167,986,868
TOTAL ASSETS	183,136,138	189,605,225
CURRENT LIABILITIES:
Accounts payable – trade	166,750	320,559
Accrued expenses	504,383	1,182,323
Other current liabilities	499,875	90,602
Notes payable, net	4,727,662
Current portion of operating lease liabilities	303,488	292,409
Total Current Liabilities	6,202,158	1,885,893
NON-CURRENT LIABILITIES:
Contingent consideration liability	9,029,842	6,037,945
Convertible notes payable	1,200,000	1,200,000
Notes payable, net		4,579,114
Operating lease liabilities, net of current portion	1,084,675	1,239,334
Total Liabilities	17,516,675	14,942,286
Commitments and Contingencies
STOCKHOLDERS’ EQUITY:
Preferred stock, $0.0001 par value; 10,000,000 shares authorized; no shares issued and outstanding
Common stock, par value $0.0001, 100,000,000 shares authorized, 52,633,267 shares issued and outstanding at December 31, 2021, and 52,219,661 shares issued and outstanding at June 30, 2021	5,263	5,222
Additional paid-in capital	273,539,732	265,580,356
Accumulated deficit	(107,906,715)	(90,911,805)
Accumulated other comprehensive loss	(18,817)	(10,834)
Total Stockholders’ Equity	165,619,463	174,662,939
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$ 183,136,138	$ 189,605,225

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) - $ / shares	Dec. 31, 2021	Jun. 30, 2021
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	100,000,000	100,000,000
Common Stock, shares issued	52,633,267	52,219,661
Common stock, shares outstanding	52,633,267	52,219,661

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2021	Dec. 31, 2020
Operating Expenses
General and administrative	$ 4,154,901	$ 1,939,988	$ 8,621,598	$ 3,717,911
Research and development	2,144,085	1,334,468	5,150,328	2,384,844
Depreciation and amortization	31,805	30,760	63,538	61,218
Total Operating Expenses	6,330,791	3,305,216	13,835,464	6,163,973
LOSS FROM OPERATIONS	(6,330,791)	(3,305,216)	(13,835,464)	(6,163,973)
Other Income (Expense)
Change in fair value of contingent consideration	(167,255)	493,411	(2,991,897)	920,811
Interest expense	(93,382)	(93,426)	(183,121)	(185,739)
Gain on currency transactions		(32,289)	9	(32,289)
Interest and other income	8,487	3,066	15,597	7,372
Total Other Income (Expense)	(252,150)	370,762	(3,159,412)	710,155
Loss Before Income Taxes	(6,582,941)	(2,934,454)	(16,994,876)	(5,453,818)
Income Tax (Provision) Benefit		1,158	(34)	123,952
NET LOSS	$ (6,582,941)	$ (2,933,296)	$ (16,994,910)	$ (5,329,866)
BASIC AND DILUTED LOSS PER SHARE	$ (0.13)	$ (0.06)	$ (0.33)	$ (0.11)
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING - BASIC AND DILUTED	52,321,982	46,660,304	52,270,821	46,632,711

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2021	Dec. 31, 2020
Income Statement [Abstract]
Net Loss	$ (6,582,941)	$ (2,933,296)	$ (16,994,910)	$ (5,329,866)
Foreign Currency Translation, Adjustments	(3,990)	9,933	(7,983)	38,322
Comprehensive Loss	$ (6,586,931)	$ (2,923,363)	$ (17,002,893)	$ (5,291,544)

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDER'S EQUITY (Unaudited) - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Total
September 30, 2020 at Jun. 30, 2020	$ 4,650	$ 230,497,225	$ (64,188,198)	$ (41,416)	$ 166,272,261
Beginning balance, shares at Jun. 30, 2020	46,497,409
Stock-based Compensation		326,156			326,156
Issuance of Commitment Shares Related to LPC Purchase Agreement	$ 14	(14)
Issuance of commitment shares related to LPC purchase agreement,shares	139,567
Net Loss			(2,396,570)		(2,396,570)
Currency Translations				28,389	28,389
December 31, 2020 at Sep. 30, 2020	$ 4,664	230,823,367	(66,584,768)	(13,027)	164,230,236
Ending balance, shares at Sep. 30, 2020	46,636,976
September 30, 2020 at Jun. 30, 2020	$ 4,650	230,497,225	(64,188,198)	(41,416)	166,272,261
Beginning balance, shares at Jun. 30, 2020	46,497,409
Net Loss					(5,329,866)
December 31, 2020 at Dec. 31, 2020	$ 4,676	231,457,324	(69,518,064)	(3,094)	161,940,842
Ending balance, shares at Dec. 31, 2020	46,763,220
September 30, 2020 at Sep. 30, 2020	$ 4,664	230,823,367	(66,584,768)	(13,027)	164,230,236
Beginning balance, shares at Sep. 30, 2020	46,636,976
Stock Issued Pursuant to Warrants Exercised	$ 6	82,050			82,056
Stock Issued Pursuant to Warrants Exercised, shares	63,122
Contingent Shares Issued Pursuant to Acquisition Agreement	$ 6	192,516			192,522
Contingent Shares Issued Pursuant to Acquisition Agreement, shares	63,122
Stock-based Compensation		359,391			359,391
Net Loss			(2,933,296)		(2,933,296)
Currency Translations				9,933	9,933
December 31, 2020 at Dec. 31, 2020	$ 4,676	231,457,324	(69,518,064)	(3,094)	161,940,842
Ending balance, shares at Dec. 31, 2020	46,763,220
September 30, 2020 at Jun. 30, 2021	$ 5,222	265,580,356	(90,911,805)	(10,834)	174,662,939
Beginning balance, shares at Jun. 30, 2021	52,219,661
Stock-based Compensation		2,727,975			2,727,975
Net Loss			(10,411,969)		(10,411,969)
Currency Translations				(3,993)	(3,993)
December 31, 2020 at Sep. 30, 2021	$ 5,222	268,308,331	(101,323,774)	(14,827)	166,974,952
Ending balance, shares at Sep. 30, 2021	52,219,661
September 30, 2020 at Jun. 30, 2021	$ 5,222	265,580,356	(90,911,805)	(10,834)	174,662,939
Beginning balance, shares at Jun. 30, 2021	52,219,661
Net Loss					(16,994,910)
December 31, 2020 at Dec. 31, 2021	$ 5,263	273,539,732	(107,906,715)	(18,817)	165,619,463
Ending balance, shares at Dec. 31, 2021	52,633,267
September 30, 2020 at Sep. 30, 2021	$ 5,222	268,308,331	(101,323,774)	(14,827)	166,974,952
Beginning balance, shares at Sep. 30, 2021	52,219,661
Stock Issued Pursuant to Warrants Exercised	$ 10	129,990			130,000
Stock Issued Pursuant to Warrants Exercised, shares	100,000
Shares Issued Pursuant to LPC Purchase Agreement	$ 28	3,048,311			3,048,339
Shares Issued Pursuant to LPC Purchase Agreement, shares	277,340
Stock-based Compensation		2,043,292			2,043,292
Shares issued for fully vested RSUs		9,811			9,811
Shares issued for fully vested RSUs, shares	1,266
Restricted shares converted to shares for services rendered	$ 3	(3)
Restricted shares converted to shares for services rendered, shares	35,000
Net Loss			(6,582,941)		(6,582,941)
Currency Translations				(3,990)	(3,990)
December 31, 2020 at Dec. 31, 2021	$ 5,263	$ 273,539,732	$ (107,906,715)	$ (18,817)	$ 165,619,463
Ending balance, shares at Dec. 31, 2021	52,633,267

CONDENSED CONSOLIDATED STATEM_4

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)	6 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Statement of Cash Flows [Abstract]
NET LOSS	$ (16,994,910)	$ (5,329,866)
ADJUSTMENTS TO RECONCILE NET LOSS TO NET CASH USED IN OPERATING ACTIVITIES:
Depreciation and amortization	63,538	61,218
Change in contingent consideration liability	2,991,897	(920,811)
Stock based compensation expense	4,771,267	685,547
Right-of-use assets	138,014	132,611
Amortization of discount of notes payable	148,548	147,957
CHANGES IN OPERATING ASSETS AND LIABILITIES:
Other receivables	1,640	1,982
Prepaid expenses/deposits	(11,812)	374,154
Accounts payable	(153,810)	(403,953)
Accrued expenses	(677,939)	132,542
Other current liabilities	(30,004)
Operating lease liabilities	(143,580)	(133,209)
NET CASH USED IN OPERATING ACTIVITIES	(9,897,151)	(5,251,828)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property and equipment	(5,156)	(10,721)
NET CASH USED IN INVESTING ACTIVITIES	(5,156)	(10,721)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from exercise of warrants	130,000	82,056
Repayment of finance agreement	(227,598)	(122,464)
Proceeds from LPC equity agreement	3,048,339
NET CASH PROVIDED BY (USED IN) FINANCING ACTIVITIES	2,950,741	(40,408)
Effect of exchange rates on cash	(4,937)	31,646
NET CHANGE IN CASH	(6,956,503)	(5,271,311)
CASH, BEGINNING OF PERIOD	20,664,410	8,696,361
CASH, END OF PERIOD	13,707,907	3,425,050
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION
Interest	36,462	42,365
Income Taxes	34	37
SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING ACTIVITIES
Contingent Shares issued pursuant to Acquisition Agreement		192,522
Finance agreement entered into in exchange for prepaid assets	$ 666,875	$ 607,250

THE BUSINESS AND SUMMARY OF SIG

THE BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	6 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
THE BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 1 — THE BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Business Basis of Presentation Consolidation Accounting Estimates COVID-19 The full extent to which the COVID-19 pandemic may impact our business and operations is subject to future developments, which are uncertain and difficult to predict. Further quarantines, shelter-in-place or similar restrictions and other actions taken or imposed by foreign, federal, state and local governments could adversely impact our or our partners’ clinical, research and development, regulatory and manufacturing operations or timelines. We continue to monitor the impact of the COVID-19 pandemic on our business and operations and will seek to adjust our activities as appropriate. In addition, the pandemic could result in significant and prolonged disruption of global financial markets, reducing our ability to access capital, which could in the future negatively affect the financial resources available to us. Functional Currency & Foreign Currency Translation Cash and Cash Equivalents 13,423,820 20,287,212 Property and Equipment Intangible Assets Definite life intangible assets include patents. The Company accounts for definite life intangible assets in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 350, “Goodwill and Other Intangible Assets”. Intangible assets are recorded at cost. Patent costs consist of costs incurred to acquire the underlying patent. If it is determined that a patent will not be issued, the related remaining capitalized patent costs are charged to expense. Intangible assets are amortized on a straight-line basis over their estimated useful life. The estimated useful life of patents is twenty years from the date of application. Indefinite life intangible assets include license agreements and goodwill. The Company accounts for indefinite life intangible assets in accordance with ASC 350, “Goodwill and Other Intangible Assets”. License agreement costs represent the fair value of the license agreement on the date acquired and are tested annually for impairment, as well as whever events or changes in circumstances indicate the carrying value may not be recoverable. The fair value analysis performed on the license agreements, and the fair value analysis performed on goodwill supported that both indefinite life intangible assets are not impaired as of June 30, 2021 (see Note 4.) Goodwill th Impairment of Goodwill and Indefinite Lived Intangible Assets 154,824,000 11,640,000 For indefinite-lived intangible assets, such as licenses acquired as an IPR&D asset, on an annual basis we determine the fair value of the asset and record an impairment loss, if any, for the excess of the carrying value of the asset over its fair value. The fair value analysis performed on the license agreement, and the annual fair value analysis performed on goodwill supported that both indefinite life intangible assets are not impaired as of June 30, 2021, and no impairment is deemed necessary as of December 31, 2021 (see Note 4.) Impairment of Long-Lived Assets Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, an impairment charge is recognized for the amount by which the carrying amount of the asset exceeds the fair value of the asset. Assets to be disposed of would be separately presented in the balance sheet and reported at the lower of the carrying amount or fair value less costs to sell and would no longer be depreciated. The depreciable basis of assets that are impaired and continue in use are their respective fair values. Leases Rent expense for operating leases is recognized on a straight-line basis, unless the operating lease right of use assets have been impaired, over the reasonably assured lease term based on the total lease payments and is included in operating expense in the condensed consolidated statements of operations. For operating leases that reflect impairment, the Company will recognize the amortization of the operating lease right-of-use assets on a straight-line basis over the remaining lease term with rent expense still included in general and administrative expenses in the unaudited condensed consolidated statements of operations. The Company has elected the practical expedient to not separate lease and non-lease components. The Company’s non-lease components are primarily related to property maintenance, insurance and taxes, which vary based on future outcomes, and thus are recognized in general and administrative expenses when incurred (see Note 5.) Research and Development Expenses 2,144,085 5,150,328 1,334,468 2,384,844 Income Taxes Loss Per Share 7,125,894 4,072,275 Fair Value of Financial Instruments Stock Options and Restricted Share Units Stock-Based Compensation 2,043,292 4,771,267 359,391 668,482 Recently Adopted Accounting Pronouncements

FAIR VALUE MEASUREMENTS

FAIR VALUE MEASUREMENTS	6 Months Ended
	Dec. 31, 2021
Fair Value Measurements
FAIR VALUE MEASUREMENTS	NOTE 2 — FAIR VALUE MEASUREMENTS ● Level 1. Observable inputs such as quoted prices in active markets for identical assets or liabilities; ● Level 2. Inputs, other than quoted prices in active markets, that are observable either directly or indirectly; and ● Level 3. Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions. There were no Level 1, 2 or 3 assets, nor any Level 1 or 2 liabilities as of December 31, 2021. Level 3 liabilities held as of December 31, 2021 consisted of a contingent consideration liability related to the February 16, 2018 acquisition of Enochian Biopharma Inc. (the “Acquisition”). As consideration for the Acquisition, the stockholders of Enochian Biopharma received (i) 18,081,962 21,516,000 1,250,000 The fair value of the contingent consideration liability is estimated using an option-pricing model. The key inputs to the model are all contractual or observable with the exception being volatility, which is computed, based on the Company’s underlying stock. The key inputs to valuing the contingent consideration liability as of December 31, 2021, include the Company’s stock price on the valuation date of $ 7.29 1.30 0.20 88.4 99 1,250,000 Unless otherwise disclosed, the fair value of the Company’s financial instruments including cash, accounts receivable, prepaid expenses, investments, accounts payable, accrued expenses, capital lease obligations and notes payable approximate their recorded values due to their short-term maturities. The following table sets forth the Level 3 liability at December 31, 2021, which is recorded on the balance sheet at fair value on a recurring basis. As required, this liability is classified based on the lowest level of input that is significant to the fair value measurement: Summary of significant to the fair value measurement Fair Value Measurements at Quoted Prices in Significant Other Significant Other Unobservable Inputs (Level 1) (Level 2) (Level 3) The roll forward of the contingent consideration liability is as follows: Balance June 30, 2021 — — $ 6,037,945 Contingent Shares issued pursuant to the Acquisition Agreement — — — Fair value adjustment — — 2,991,897 Contingent Consideration Liability at December 31, 2021 — — $ 9,029,842

PROPERTY AND EQUIPMENT

PROPERTY AND EQUIPMENT	6 Months Ended
	Dec. 31, 2021
Property, Plant and Equipment [Abstract]
PROPERTY AND EQUIPMENT	NOTE 3 — PROPERTY AND EQUIPMENT Summary of property and equipment Useful Life December 31, 2021 June 30, 2021 Lab Equipment and Instruments 4 7 $ 583,421 $ 583,421 Leasehold Improvements 10 224,629 224,629 Furniture Fixtures and Equipment 4 7 177,131 171,975 Total 985,181 980,025 Less Accumulated Depreciation (316,457 ) (260,661 ) Net Property and Equipment $ 668,723 $ 719,364 Depreciation expense amounted to $ 27,990 55,796 26,813 53,358

INTANGIBLE ASSETS

INTANGIBLE ASSETS	6 Months Ended
	Dec. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
INTANGIBLE ASSETS	NOTE 4 — INTANGIBLE ASSETS At December 31, 2021 and June 30, 2021, definite-life intangible assets, net of accumulated amortization, consisted of patents on the Company’s products and processes of $ 55,413 65,906 3,814 7,741 3,947 7,859 At December 31, 2021 and 2020, indefinite life intangibles assets consisted of a license agreement classified as In-Process Research and Development (“IPR&D”) intangible assets, which are not amortizable until the intangible asset provides economic benefit, and goodwill. At December 31, 2021 and June 30, 2021, definite and indefinite-life intangible assets consisted of the following: Schedule of life intangible assets Useful Life June 30, Period Change Effect of Currency Translation December 31 , Definite Life Intangible Assets Patents 20 $ 316,115 $ — $ (14,145 ) $ 301,970 Less Accumulated Amortization (250,209 ) (7,741 ) 11,393 (246,557 ) Net Definite-Life Intangible Assets $ 65,906 $ (7,741 ) $ (2,752 ) $ 55,413 Indefinite Life Intangible Assets License Agreement $ 154,824,000 — — $ 154,824,000 Goodwill 11,640,000 — — 11,640,000 Total Indefinite Life Intangible Assets $ 166,464,000 — — $ 166,464,000 Expected future amortization expense is as follows: Schedule of expected future amortization expense Year ending June 30, 2022 $ 4,661 2023 15,154 2024 15,154 2025 15,154 2026 5,290 Thereafter — Total $ 55,413 During February 2018, the Company acquired a License Agreement (as licensee) to an HIV therapy which consists of a perpetual, fully paid-up, royalty-free, sub-licensable, and sole and exclusive worldwide license to research, develop, use, sell, have sold, make, have made, offer for sale, import and otherwise commercialize certain intellectual property in cellular therapies for the prevention, treatment, amelioration of and/or therapy exclusively for HIV in humans, and research and development exclusively relating to HIV in humans. Because the HIV License Agreement is considered an IPR&D intangible asset it is classified as an indefinite life asset that is tested annually for impairment. Impairment – Following the fourth quarter of each year, management performs its annual test of impairment of intangible assets by performing a quantitative assessment and determines if it is more likely than not that, the fair value of the asset is greater than or equal to the carrying value of the asset. The results of the quantitative assessment supported Management’s conclusion that an impairment adjustment was not required as of June 30, 2021, and no impairment is deemed necessary as of December 31, 2021.

LEASES

LEASES	6 Months Ended
	Dec. 31, 2021
Leases
LEASES	NOTE 5 — LEASES Operating Leases On November 13, 2017, Enochian entered into a Lease Agreement for a term of five years and two months from November 1, 2017, with Plaza Medical Office Building, LLC, a California limited liability company (the “Landlord”), as landlord, pursuant to which the Company agreed to lease from the Landlord approximately 2,325 rentable square feet. The base rent increases by 3% each year, and ranges from approximately $8,719 per month for the first year to $10,107 per month for the two months of the sixth year On June 19, 2018, the Registrant entered into a Lease Agreement for a term of ten years from September 1, 2018, with Century City Medical Plaza Land Co., Inc., pursuant to which the Company agreed to lease approximately 2,453 rentable square feet. On February 20, 2019, the Registrant entered into an Addendum to the original Lease Agreement with an effective date of December 1, 2019, where it expanded the lease area to include another 1,101 square feet for a total rentable 3,554 square feet. The base rent increases by 3% each year, and ranges from $17,770 per month for the first year to $23,186 per month for the tenth year. The equalized monthly lease payment for the term of the lease is $20,050 The Company identified and assessed the following significant assumptions in recognizing the right-of-use asset and corresponding liabilities: Expected lease term 5.28 Incremental borrowing rate 4.01 Lease and non-lease components Lease expense charged to general and administrative expenses for the three and six months ended December 31, 2021, amounted to $ 84,113 168,196 88,690 178,374 Below are the lease commitments for the next 5 years and thereafter: Lease commitments Year Ending June 30 th Lease Expense 2022 $ 175,419 2023 298,305 2024 246,004 2025 253,384 2026 260,985 Thereafter 313,836 Less imputed interest (159,770 ) Total $ 1,388,163

NOTES PAYABLE

NOTES PAYABLE	6 Months Ended
	Dec. 31, 2021
Debt Disclosure [Abstract]
NOTES PAYABLE	NOTE 6 — NOTES PAYABLE Convertible Notes Payable 600,000 February 6, 2023 6 The holder of the Convertible Notes had the right at any time prior to the date that is twelve months from issuance to convert all or any part of the outstanding and unpaid principal and all unpaid interest into shares of the Company’s Common Stock. The conversion price is equal to $ 12.00 1,200,000 24,181 18,181 36,453 Note Payable 5,000,000 November 30, 2021 6 188,485 501,370 493,192 493,192 On February 11, 2021, the Company entered into an amendment to the Unsecured Note in the principal amount of $ 5,000,000 6 74,054 298,178 74,274 148,548 73,979 147,958 4,727,662 Finance Agreement 666,875 3.99 56,469 For the three and six months ended December 31, 2021, the Company recorded total interest expense in the amount of $ 927 Total interest expense recorded for the three and six months ended December 31, 2021, was $ 93,382 183,121 93,426 185,739

STOCKHOLDERS_ EQUITY

STOCKHOLDERS’ EQUITY	6 Months Ended
	Dec. 31, 2021
Equity [Abstract]
STOCKHOLDERS’ EQUITY	NOTE 7 — STOCKHOLDERS’ EQUITY Preferred Stock 10,000,000 0.0001 Common Stock 100,000,000 0.0001 52,633,267 52,219,661 Voting — Dividends — Liquidation Rights — Purchase Agreement with Lincoln Park Capital On July 8, 2020, we entered into a purchase agreement (the “Purchase Agreement”) with Lincoln Park Capital Fund, LLC (“Lincoln Park”), pursuant to which the Company may sell and issue to Lincoln Park, and Lincoln Park is obligated to purchase, up to $ 20,000,000 Under the Purchase Agreement, we may direct Lincoln Park, at our sole discretion subject to certain conditions, to purchase up to 200,000 125,000 1,000,000 Our sale of shares of Common Stock to Lincoln Park subsequent to the Amendment Date is limited to 12,016,457 shares of Common Stock, representing 19.99% In consideration for entering into the Purchase Agreement, we issued 139,567 During the three and six months ended December 31, 2021, we issued 277,340 3,048,339 Common Stock Issuances — 413,606 126,244 265,811 Acquisition of Enochian Biopharma Inc. / Contingently issuable shares — 1,250,000 Acquisition of Enochian Denmark — 17,414 167,639 Stock-based Compensation The Company recognizes compensation costs for stock option awards to employees and directors based on their grant-date fair value. The value of each stock option is estimated on the date of grant using the Black-Scholes option-pricing model. The weighted-average assumptions used to estimate the fair values of the stock options granted using the Black-Scholes option-pricing model are as follows: Summary of weighted-average assumptions used to estimate the fair values of the stock options granted Enochian Biosciences Inc. Expected term (in years) 5.0 6.5 Volatility 82.39 90.21 Risk free interest rate 0.77 1.33 Dividend yield 0 The Company recognized stock-based compensation expense related to the options of $ 2,043,292 4,771,267 359,391 668,482 8,571,250 Plan Options On February 6, 2014, the Board adopted the Company’s 2014 Equity Incentive Plan (the “2014 Plan”), and the Company had reserved 1,206,000 On October 30, 2019, the Board approved and on October 31, 2019, the Company’s shareholders adopted Enochian’s 2019 Equity Incentive Plan (the “2019 Plan”), which replaced the 2014 Plan. The 2019 Plan authorized options to be awarded to not exceed the sum of (1) 6,000,000 new shares of Common Stock, and (2) the number of shares of Common Stock available for the grant of awards as of the effective date under the 2014 Plan that, after the effective date of the 2019 Plan, expires, or is terminated, surrendered, or forfeited for any reason without issuance of shares. The remaining shares of Common Stock available for grant related to the 2014 Plan was 655,769 as of the effective date; this amount along with the new 6,000,000 shares totals 6,655,769 shares of Common Stock were available to grant immediately after the effective date of the 2019 Plan. Pursuant to the 2019 Plan, the Company granted options to purchase 120,900 3,130,200 3 9,201 3 During the three and six months ended December 31, 2021, the Company granted options to purchase 36,727 63,462 63,435 87,631 The Company issued options to purchase 21,979 17,500 60,000 To date the Company has granted options under the Plan (“Plan Options”) to purchase 4,629,294 A summary of the status of the Plan Options outstanding at December 31, 2021 is presented below: Summary of stock option activity Options Outstanding Options Exercisable Exercise Price Ranges Number Outstanding Weighted Average Remaining Contractual Life (years) Weighted Average Exercise Price Number Exercisable Weighted Average Remaining Contractual Life (years) Weighted Average Exercise Price $ 2.00 4.50 285,043 8.69 $ 3.23 197,637 8.49 $ 3.12 $ 4.51 6.50 3,538,330 9.21 $ 4.80 455,999 7.09 $ 6.16 $ 6.51 8.00 797,521 8.70 $ 7.95 556,094 8.20 $ 7.93 Total 4,620,894 9.09 $ 5.25 1,209,730 7.83 $ 6.48 A summary of the status of the Plan Options at December 31, 2021 and changes since July 1, 2021 are presented below: Summary of stock option activity Shares Weighted Average Exercise Price Average Remaining Life Weighted Average Intrinsic Value Outstanding at beginning of period 1,329,153 $ 6.24 8.42 $ 511,239 Granted 3,300,141 $ 4.85 10.0 $ — Exercised — $ — — $ — Forfeited — $ — — $ — Expired (8,400 ) $ — — $ — Outstanding at end of period 4,620,894 $ 5.25 9.09 $ 9,997,233 Exercisable end of period 1,209,730 $ 6.48 7.83 $ 1,352,948 At December 31, 2021, the Company had 1,209,730 1,352,948 Common Stock Purchase Warrants A summary of the warrants outstanding at December 31, 2021, are presented below: Summary of common stock purchase warrants outstanding Shares Weighted Average Exercise Weighted Average Remaining Outstanding at beginning of period 1,350,000 $ 1.30 1.02 Granted — $ — — Exercised (100,000 ) $ 1.30 — Cancelled/Expired — $ — — Outstanding and exercisable at end of period 1,250,000 $ 1.30 .53 Summary of common stock purchase warrants Underlying Warrants Outstanding Equivalent Shares Exercisable Exercise Prices Equivalent Shares Weighted Average Remaining Contractual Life (years) Weighted Average Exercise Price Number Exercisable Weighted Average Exercise Price $ 1.30 1,250,000 .53 $ 1.30 1,250,000 $ 1.30 The exercise price of certain warrants and the number of shares underlying the warrants are subject to adjustment for stock dividends, subdivisions of the outstanding shares of Common Stock and combinations of the outstanding shares of Common Stock. For so long as the warrants remain outstanding, we are required to keep reserved from our authorized and unissued shares of Common Stock a sufficient number of shares to provide for the issuance of the shares underlying the warrants. Restricted Stock Units (RSUs) The Company recognized stock-based compensation expense related to RSUs of $ 255,340 258,331 7,860 17,066 A summary of the status of Restricted Stock Units outstanding at December 31, 2021 is presented below: Summary of restricted stock units outstanding Shares Weighted Average Issuance Price Weighted Average Remaining Life Weighted Average Intrinsic Value Outstanding at beginning of period 5,000 $ 6.15 .02 $ — Granted 36,266 — — — Exercised (36,266 ) — — — Cancelled/Expired — — — — Outstanding at end of period 5,000 6.15 .02 $ — Summary of restricted stock units activity Restricted Stock Units Outstanding Grant Price Stock Units Weighted Average Remaining Contractual Life (years) Weighted Average Issuance Price 6.15 5,000 .02 $ 6.15

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	6 Months Ended
	Dec. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 8 — COMMITMENTS AND CONTINGENCIES On July 9, 2018, the Company entered into a consulting agreement with G-Tech Bio, LLC, a California limited liability company (“G-Tech”) to assist the Company with the development of the gene therapy and cell therapy modalities for the prevention, treatment, and amelioration of HIV in humans, and with the development of a genetically enhanced Dendritic Cell for use as a wide spectrum platform for various diseases (including but not limited to cancers and infectious diseases) (the “G-Tech Agreement”). G-Tech was entitled to consulting fees for 20 months, with a monthly consulting fee of not greater than $130,000 per month. Upon the completion of the 20 months, the monthly consulting fee of $ 25,000 75,000 150,000 75,000 125,000 On January 31, 2020, the Company entered into a Statement of Work & License Agreement (the “HBV License Agreement”) by and among the Company, G-Tech , and G Health Research Foundation, a not for profit entity organized under the laws of California doing business as Seraph Research Institute (“SRI”), whereby the Company acquired a perpetual, sublicensable, exclusive license (the “HBV License”) for a treatment under development (the “Treatment”) aimed to treat Hepatitis B Virus (HBV) infections in accordance with its agreement in principle with G-Tech and SRI. The HBV License Agreement contains customary representations, warranties and covenants of the parties with respect to the development of the Treatment and the HBV License. G-Tech and SRI are each controlled by certain members of Weird Science, LLC, a shareholder of the Company. The cash funding for research costs pursuant to the HBV License Agreement consists of monthly payments amounting to $ 144,500 433,500 867,000 1,500,000 On April 18, 2021, the Company entered into a Statement of Work and License Agreement (the “License Agreement”), by and among the Company, G-Tech and SRI, whereby the Company acquired a perpetual sublicensable, exclusive license (the “Development License”) to research, develop, and commercialize certain formulations which are aimed at preventing and treating pan-coronavirus or the potential combination of the pan-coronavirus and pan-influenza, including the SARS-coronavirus that causes COVID-19 and pan-influenza (the “Prevention and Treatment”). The License Agreement was entered into pursuant to the existing Framework Agreement between the parties dated November 15, 2019. The License Agreement states that in consideration for the Development License, the Company shall provide cash funding for research costs and equipment and certain other in-kind funding related to the Prevention and Treatment over a 24-month period. Additionally, the License Agreement provides for an up-front payment of $ 10,000,000 760,000 The License Agreement provides for cooperation related to the development of intellectual property related to the Prevention and Treatment and for a 3% royalty to G-Tech on any net sales that may occur under the License Agreement. For the three and six months ended December 31, 2021, the Company paid $ 75,000 150,000 G-Tech is controlled by Dr. Serhat Gümrükcü and Anderson Wittekind, shareholders of the Company, and SRI is controlled by Dr. Serhat Gümrükcü. Shares held for non-consenting shareholders – Service Agreements – 210,000 Contingencies

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	6 Months Ended
	Dec. 31, 2021
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	NOTE 9 — RELATED PARTY TRANSACTIONS The Company paid G-Tech $ 718,500 3,537,000

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	6 Months Ended
	Dec. 31, 2021
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 10 — SUBSEQUENT EVENTS In accordance with ASC 855-10, the Company performed a review of events subsequent to the balance sheet date and through the date of this report and determined that there were no such events requiring recognition or disclosure.

THE BUSINESS AND SUMMARY OF S_2

THE BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	6 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
Business	Business
Basis of Presentation	Basis of Presentation
Consolidation	Consolidation
Accounting Estimates	Accounting Estimates
COVID-19	COVID-19 The full extent to which the COVID-19 pandemic may impact our business and operations is subject to future developments, which are uncertain and difficult to predict. Further quarantines, shelter-in-place or similar restrictions and other actions taken or imposed by foreign, federal, state and local governments could adversely impact our or our partners’ clinical, research and development, regulatory and manufacturing operations or timelines. We continue to monitor the impact of the COVID-19 pandemic on our business and operations and will seek to adjust our activities as appropriate. In addition, the pandemic could result in significant and prolonged disruption of global financial markets, reducing our ability to access capital, which could in the future negatively affect the financial resources available to us.
Functional Currency & Foreign Currency Translation	Functional Currency & Foreign Currency Translation
Cash and Cash Equivalents	Cash and Cash Equivalents 13,423,820 20,287,212
Property and Equipment	Property and Equipment
Intangible Assets	Intangible Assets Definite life intangible assets include patents. The Company accounts for definite life intangible assets in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 350, “Goodwill and Other Intangible Assets”. Intangible assets are recorded at cost. Patent costs consist of costs incurred to acquire the underlying patent. If it is determined that a patent will not be issued, the related remaining capitalized patent costs are charged to expense. Intangible assets are amortized on a straight-line basis over their estimated useful life. The estimated useful life of patents is twenty years from the date of application. Indefinite life intangible assets include license agreements and goodwill. The Company accounts for indefinite life intangible assets in accordance with ASC 350, “Goodwill and Other Intangible Assets”. License agreement costs represent the fair value of the license agreement on the date acquired and are tested annually for impairment, as well as whever events or changes in circumstances indicate the carrying value may not be recoverable. The fair value analysis performed on the license agreements, and the fair value analysis performed on goodwill supported that both indefinite life intangible assets are not impaired as of June 30, 2021 (see Note 4.)
Goodwill	Goodwill th
Impairment of Goodwill and Indefinite Lived Intangible Assets	Impairment of Goodwill and Indefinite Lived Intangible Assets 154,824,000 11,640,000 For indefinite-lived intangible assets, such as licenses acquired as an IPR&D asset, on an annual basis we determine the fair value of the asset and record an impairment loss, if any, for the excess of the carrying value of the asset over its fair value. The fair value analysis performed on the license agreement, and the annual fair value analysis performed on goodwill supported that both indefinite life intangible assets are not impaired as of June 30, 2021, and no impairment is deemed necessary as of December 31, 2021 (see Note 4.)
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, an impairment charge is recognized for the amount by which the carrying amount of the asset exceeds the fair value of the asset. Assets to be disposed of would be separately presented in the balance sheet and reported at the lower of the carrying amount or fair value less costs to sell and would no longer be depreciated. The depreciable basis of assets that are impaired and continue in use are their respective fair values.
Leases	Leases Rent expense for operating leases is recognized on a straight-line basis, unless the operating lease right of use assets have been impaired, over the reasonably assured lease term based on the total lease payments and is included in operating expense in the condensed consolidated statements of operations. For operating leases that reflect impairment, the Company will recognize the amortization of the operating lease right-of-use assets on a straight-line basis over the remaining lease term with rent expense still included in general and administrative expenses in the unaudited condensed consolidated statements of operations. The Company has elected the practical expedient to not separate lease and non-lease components. The Company’s non-lease components are primarily related to property maintenance, insurance and taxes, which vary based on future outcomes, and thus are recognized in general and administrative expenses when incurred (see Note 5.)
Research and Development Expenses	Research and Development Expenses 2,144,085 5,150,328 1,334,468 2,384,844
Income Taxes	Income Taxes
Loss Per Share	Loss Per Share 7,125,894 4,072,275
Fair Value of Financial Instruments	Fair Value of Financial Instruments
Stock Options and Restricted Share Units	Stock Options and Restricted Share Units
Stock-Based Compensation	Stock-Based Compensation 2,043,292 4,771,267 359,391 668,482
Recently Adopted Accounting Pronouncements	Recently Adopted Accounting Pronouncements

FAIR VALUE MEASUREMENTS (Tables

FAIR VALUE MEASUREMENTS (Tables)	6 Months Ended
	Dec. 31, 2021
Fair Value Measurements
Summary of significant to the fair value measurement	Summary of significant to the fair value measurement Fair Value Measurements at Quoted Prices in Significant Other Significant Other Unobservable Inputs (Level 1) (Level 2) (Level 3) The roll forward of the contingent consideration liability is as follows: Balance June 30, 2021 — — $ 6,037,945 Contingent Shares issued pursuant to the Acquisition Agreement — — — Fair value adjustment — — 2,991,897 Contingent Consideration Liability at December 31, 2021 — — $ 9,029,842

PROPERTY AND EQUIPMENT (Tables)

PROPERTY AND EQUIPMENT (Tables)	6 Months Ended
	Dec. 31, 2021
Property, Plant and Equipment [Abstract]
Summary of property and equipment	Summary of property and equipment Useful Life December 31, 2021 June 30, 2021 Lab Equipment and Instruments 4 7 $ 583,421 $ 583,421 Leasehold Improvements 10 224,629 224,629 Furniture Fixtures and Equipment 4 7 177,131 171,975 Total 985,181 980,025 Less Accumulated Depreciation (316,457 ) (260,661 ) Net Property and Equipment $ 668,723 $ 719,364

INTANGIBLE ASSETS (Tables)

INTANGIBLE ASSETS (Tables)	6 Months Ended
	Dec. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of life intangible assets	Schedule of life intangible assets Useful Life June 30, Period Change Effect of Currency Translation December 31 , Definite Life Intangible Assets Patents 20 $ 316,115 $ — $ (14,145 ) $ 301,970 Less Accumulated Amortization (250,209 ) (7,741 ) 11,393 (246,557 ) Net Definite-Life Intangible Assets $ 65,906 $ (7,741 ) $ (2,752 ) $ 55,413 Indefinite Life Intangible Assets License Agreement $ 154,824,000 — — $ 154,824,000 Goodwill 11,640,000 — — 11,640,000 Total Indefinite Life Intangible Assets $ 166,464,000 — — $ 166,464,000
Schedule of expected future amortization expense	Schedule of expected future amortization expense Year ending June 30, 2022 $ 4,661 2023 15,154 2024 15,154 2025 15,154 2026 5,290 Thereafter — Total $ 55,413

LEASES (Tables)

LEASES (Tables)	6 Months Ended
	Dec. 31, 2021
Leases
Lease commitments	Lease commitments Year Ending June 30 th Lease Expense 2022 $ 175,419 2023 298,305 2024 246,004 2025 253,384 2026 260,985 Thereafter 313,836 Less imputed interest (159,770 ) Total $ 1,388,163

STOCKHOLDERS_ EQUITY (Tables)

STOCKHOLDERS’ EQUITY (Tables)	6 Months Ended
	Dec. 31, 2021
Equity [Abstract]
Summary of weighted-average assumptions used to estimate the fair values of the stock options granted	Summary of weighted-average assumptions used to estimate the fair values of the stock options granted Enochian Biosciences Inc. Expected term (in years) 5.0 6.5 Volatility 82.39 90.21 Risk free interest rate 0.77 1.33 Dividend yield 0
Summary of stock option activity	Summary of stock option activity Options Outstanding Options Exercisable Exercise Price Ranges Number Outstanding Weighted Average Remaining Contractual Life (years) Weighted Average Exercise Price Number Exercisable Weighted Average Remaining Contractual Life (years) Weighted Average Exercise Price $ 2.00 4.50 285,043 8.69 $ 3.23 197,637 8.49 $ 3.12 $ 4.51 6.50 3,538,330 9.21 $ 4.80 455,999 7.09 $ 6.16 $ 6.51 8.00 797,521 8.70 $ 7.95 556,094 8.20 $ 7.93 Total 4,620,894 9.09 $ 5.25 1,209,730 7.83 $ 6.48
Summary of stock option activity	Summary of stock option activity Shares Weighted Average Exercise Price Average Remaining Life Weighted Average Intrinsic Value Outstanding at beginning of period 1,329,153 $ 6.24 8.42 $ 511,239 Granted 3,300,141 $ 4.85 10.0 $ — Exercised — $ — — $ — Forfeited — $ — — $ — Expired (8,400 ) $ — — $ — Outstanding at end of period 4,620,894 $ 5.25 9.09 $ 9,997,233 Exercisable end of period 1,209,730 $ 6.48 7.83 $ 1,352,948
Summary of common stock purchase warrants outstanding	Summary of common stock purchase warrants outstanding Shares Weighted Average Exercise Weighted Average Remaining Outstanding at beginning of period 1,350,000 $ 1.30 1.02 Granted — $ — — Exercised (100,000 ) $ 1.30 — Cancelled/Expired — $ — — Outstanding and exercisable at end of period 1,250,000 $ 1.30 .53
Summary of common stock purchase warrants	Summary of common stock purchase warrants Underlying Warrants Outstanding Equivalent Shares Exercisable Exercise Prices Equivalent Shares Weighted Average Remaining Contractual Life (years) Weighted Average Exercise Price Number Exercisable Weighted Average Exercise Price $ 1.30 1,250,000 .53 $ 1.30 1,250,000 $ 1.30
Summary of restricted stock units outstanding	Summary of restricted stock units outstanding Shares Weighted Average Issuance Price Weighted Average Remaining Life Weighted Average Intrinsic Value Outstanding at beginning of period 5,000 $ 6.15 .02 $ — Granted 36,266 — — — Exercised (36,266 ) — — — Cancelled/Expired — — — — Outstanding at end of period 5,000 6.15 .02 $ —
Summary of restricted stock units activity	Summary of restricted stock units activity Restricted Stock Units Outstanding Grant Price Stock Units Weighted Average Remaining Contractual Life (years) Weighted Average Issuance Price 6.15 5,000 .02 $ 6.15

THE BUSINESS AND SUMMARY OF S_3

THE BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2021	Dec. 31, 2020	Jun. 30, 2021
Accounting Policies [Abstract]
Cash held in financial institutions	$ 13,423,820		$ 13,423,820		$ 20,287,212
In-Process Research & Development	154,824,000		154,824,000
Goodwill	11,640,000		11,640,000		$ 11,640,000
Research and development expense	2,144,085	$ 1,334,468	$ 5,150,328	$ 2,384,844
Potential dilutive shares			7,125,894	4,072,275
Stock-based compensation	$ 2,043,292	$ 359,391	$ 4,771,267	$ 668,482

FAIR VALUE MEASUREMENTS (Detail

FAIR VALUE MEASUREMENTS (Details) - USD ($)	6 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Defined Benefit Plan Disclosure [Line Items]
Contingent Shares issued pursuant to the Acquisition Agreement		$ 192,522
Fair Value, Inputs, Level 1 [Member]
Defined Benefit Plan Disclosure [Line Items]
Balance at beginning
Contingent Shares issued pursuant to the Acquisition Agreement
Fair value adjustment
Balance at end
Fair Value, Inputs, Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Balance at beginning
Contingent Shares issued pursuant to the Acquisition Agreement
Fair value adjustment
Balance at end
Fair Value, Inputs, Level 3 [Member]
Defined Benefit Plan Disclosure [Line Items]
Balance at beginning	6,037,945
Contingent Shares issued pursuant to the Acquisition Agreement
Fair value adjustment	2,991,897
Balance at end	$ 9,029,842

FAIR VALUE MEASUREMENTS (Deta_2

FAIR VALUE MEASUREMENTS (Details Narrative) - USD ($)	Feb. 16, 2018	Dec. 31, 2021
Acquisition of Enochian Biopharma [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Stock price		$ 7.29
Exercise price of warrants		$ 1.30
Risk-free rate		0.20%
Expected volatility		88.40%
Digital call rate		99.00%
Outstanding contingent shares		1,250,000
Agreement and Plan of Merger (the "Acquisition Agreement") [Member] | Enochian Biopharma Inc. and Weird Science LLC [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Shares issued on business combination	18,081,962	1,250,000
Contingent consideration liability	$ 21,516,000

PROPERTY AND EQUIPMENT (Details

PROPERTY AND EQUIPMENT (Details) - USD ($)	6 Months Ended
	Dec. 31, 2021	Jun. 30, 2021
Property, Plant and Equipment [Line Items]
Total	$ 985,181	$ 980,025
Less Accumulated Depreciation	(316,457)	(260,661)
Net Property and Equipment	668,723	719,364
Lab Equipment And Instruments [Member]
Property, Plant and Equipment [Line Items]
Total	$ 583,421	583,421
Lab Equipment And Instruments [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Useful Life	4 years
Lab Equipment And Instruments [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Useful Life	7 years
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Useful Life	10 years
Total	$ 224,629	224,629
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Total	$ 177,131	$ 171,975
Furniture and Fixtures [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Useful Life	4 years
Furniture and Fixtures [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Useful Life	7 years

PROPERTY AND EQUIPMENT (Detai_2

PROPERTY AND EQUIPMENT (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2021	Dec. 31, 2020
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 27,990	$ 26,813	$ 55,796	$ 53,358

INTANGIBLE ASSETS AND GOODWILL

INTANGIBLE ASSETS AND GOODWILL (Details) - USD ($)	6 Months Ended
	Dec. 31, 2021	Jun. 30, 2021
Finite-Lived Intangible Assets [Line Items]
Definite-life intangible assets	$ 55,413	$ 65,906
Period Change	(7,741)
Effect of Currency Translation	(2,752)
Indefinite Life Intangible Assets	$ 166,464,000	166,464,000
Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Useful Life	20 years
Definite-life intangible assets	$ 301,970	316,115
Period Change	0
Effect of Currency Translation	(14,145)
Accumulated Amortization [Member]
Finite-Lived Intangible Assets [Line Items]
Period Change	(7,741)
Effect of Currency Translation	11,393
Accumulated Amortization	(246,557)	(250,209)
Licensing Agreements [Member]
Finite-Lived Intangible Assets [Line Items]
Indefinite Life Intangible Assets	154,824,000	154,824,000
Goodwill [Member]
Finite-Lived Intangible Assets [Line Items]
Indefinite Life Intangible Assets	$ 11,640,000	$ 11,640,000

INTANGIBLE ASSETS AND GOODWIL_2

INTANGIBLE ASSETS AND GOODWILL (Details 1) - USD ($)	Dec. 31, 2021	Jun. 30, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
2022	$ 4,661
2023	15,154
2024	15,154
2025	15,154
2026	5,290
Thereafter
Total	$ 55,413	$ 65,906

INTANGIBLE ASSETS (Details Narr

INTANGIBLE ASSETS (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2021	Dec. 31, 2020	Jun. 30, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Definite-life intangible assets	$ 55,413		$ 55,413		$ 65,906
Amortization expense	$ 3,814	$ 3,947	$ 7,741	$ 7,859

LEASES (Details)

LEASES (Details)	Dec. 31, 2021USD ($)
Leases
2022	$ 175,419
2023	298,305
2024	246,004
2025	253,384
2026	260,985
Thereafter	313,836
Less imputed interest	(159,770)
Total	$ 1,388,163

LEASES (Details Narrative)

LEASES (Details Narrative) - USD ($)	Nov. 13, 2018	Jun. 19, 2019	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2021	Dec. 31, 2020
Leases
Lease premises, description	On November 13, 2017, Enochian entered into a Lease Agreement for a term of five years and two months from November 1, 2017, with Plaza Medical Office Building, LLC, a California limited liability company (the “Landlord”), as landlord, pursuant to which the Company agreed to lease from the Landlord approximately 2,325 rentable square feet. The base rent increases by 3% each year, and ranges from approximately $8,719 per month for the first year to $10,107 per month for the two months of the sixth year	On June 19, 2018, the Registrant entered into a Lease Agreement for a term of ten years from September 1, 2018, with Century City Medical Plaza Land Co., Inc., pursuant to which the Company agreed to lease approximately 2,453 rentable square feet. On February 20, 2019, the Registrant entered into an Addendum to the original Lease Agreement with an effective date of December 1, 2019, where it expanded the lease area to include another 1,101 square feet for a total rentable 3,554 square feet. The base rent increases by 3% each year, and ranges from $17,770 per month for the first year to $23,186 per month for the tenth year. The equalized monthly lease payment for the term of the lease is $20,050
Weighted-average remaining term			5 years 3 months 10 days		5 years 3 months 10 days
Weighted-average discount rate			4.01%		4.01%
Lease expense			$ 84,113	$ 88,690	$ 168,196	$ 178,374

NOTES PAYABLE (Details Narrativ

NOTES PAYABLE (Details Narrative) - USD ($)	1 Months Ended	3 Months Ended		6 Months Ended
	Nov. 30, 2021	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2021	Dec. 31, 2020	Feb. 11, 2021
Debt Instrument [Line Items]
Convertible Notes Payable, Noncurrent		$ 1,200,000	$ 1,200,000	$ 1,200,000	$ 1,200,000
Accrued interest		24,181	24,181	24,181	24,181
Interest Expense, Other		18,181	18,181	36,453	36,453
Issuance of common stock				74,054
Unsecured note principal amount	$ 666,875					$ 5,000,000
Interest at the fixed rate	3.99%					6.00%
Market price		298,178		298,178
Discount amortization		74,274	73,979	148,548	147,958
Unsecured note balance, net of discount				4,727,662
Monthly installments	$ 56,469
Interest expense related to agreement				927
interest expense		93,382	$ 93,426	183,121	$ 185,739
Convertible Notes Payables [Member]
Debt Instrument [Line Items]
Principal amount		$ 600,000		$ 600,000
Maturity date				Feb. 6, 2023
Interest rate				6.00%
Debt Instrument, Convertible, Conversion Price		$ 12		$ 12
Note Payable [Member]
Debt Instrument [Line Items]
Principal amount		$ 5,000,000		$ 5,000,000
Maturity date				Nov. 30, 2021
Interest rate				6.00%
Stock issued for debt conversion, shares				188,485
Stock issued for debt conversion				$ 501,370
Issuance of common stock				$ 493,192

STOCKHOLDERS' EQUITY (Details)

STOCKHOLDERS' EQUITY (Details) - Enochian Biosciences [Member]	6 Months Ended
	Dec. 31, 2021
Dividend yield	0.00%
Minimum [Member]
Expected term (in years)	5 years
Volatility	82.39%
Risk free interest rate	0.77%
Maximum [Member]
Expected term (in years)	6 years 6 months
Volatility	90.21%
Risk free interest rate	1.33%

STOCKHOLDERS' EQUITY (Details 1

STOCKHOLDERS' EQUITY (Details 1) - Share-based Payment Arrangement, Option [Member] - $ / shares	6 Months Ended
	Dec. 31, 2021	Jun. 30, 2021
Option Indexed to Issuer's Equity [Line Items]
Options Outstanding, Number Outstanding	4,620,894	1,329,153
Options Outstanding, Weighted Average Remaining Contractual Life (years)	9 years 1 month 2 days
Options Outstanding, Weighted Average Exercise Price	$ 5.25	$ 6.24
Options Exercisable	1,209,730
Options Exercisable, Weighted Average Remaining Contractual Life (years)	7 years 9 months 29 days
Options Exercisable, Weighted Average Exercise Price	$ 6.48
Exercise Price Range 1 [Member]
Option Indexed to Issuer's Equity [Line Items]
Options Outstanding, Number Outstanding	285,043
Options Outstanding, Weighted Average Remaining Contractual Life (years)	8 years 8 months 8 days
Options Outstanding, Weighted Average Exercise Price	$ 3.23
Options Exercisable	197,637
Options Exercisable, Weighted Average Remaining Contractual Life (years)	8 years 5 months 26 days
Options Exercisable, Weighted Average Exercise Price	$ 3.12
Exercise Price Range 1 [Member] | Minimum [Member]
Option Indexed to Issuer's Equity [Line Items]
Exercise Prices	2
Exercise Price Range 1 [Member] | Maximum [Member]
Option Indexed to Issuer's Equity [Line Items]
Exercise Prices	$ 4.50
Exercise Price Range 2 [Member]
Option Indexed to Issuer's Equity [Line Items]
Options Outstanding, Number Outstanding	3,538,330
Options Outstanding, Weighted Average Remaining Contractual Life (years)	9 years 2 months 15 days
Options Outstanding, Weighted Average Exercise Price	$ 4.80
Options Exercisable	455,999
Options Exercisable, Weighted Average Remaining Contractual Life (years)	7 years 1 month 2 days
Options Exercisable, Weighted Average Exercise Price	$ 6.16
Exercise Price Range 2 [Member] | Minimum [Member]
Option Indexed to Issuer's Equity [Line Items]
Exercise Prices	4.51
Exercise Price Range 2 [Member] | Maximum [Member]
Option Indexed to Issuer's Equity [Line Items]
Exercise Prices	$ 6.50
Exercise Price Range 3 [Member]
Option Indexed to Issuer's Equity [Line Items]
Options Outstanding, Number Outstanding	797,521
Options Outstanding, Weighted Average Remaining Contractual Life (years)	8 years 8 months 12 days
Options Outstanding, Weighted Average Exercise Price	$ 7.95
Options Exercisable	556,094
Options Exercisable, Weighted Average Remaining Contractual Life (years)	8 years 2 months 12 days
Options Exercisable, Weighted Average Exercise Price	$ 7.93
Exercise Price Range 3 [Member] | Minimum [Member]
Option Indexed to Issuer's Equity [Line Items]
Exercise Prices	6.51
Exercise Price Range 3 [Member] | Maximum [Member]
Option Indexed to Issuer's Equity [Line Items]
Exercise Prices	$ 8

STOCKHOLDERS' EQUITY (Details 2

STOCKHOLDERS' EQUITY (Details 2) - Share-based Payment Arrangement, Option [Member]	6 Months Ended
	Dec. 31, 2021USD ($)$ / sharesshares
Option Indexed to Issuer's Equity [Line Items]
Options Outstanding at beginning of period | shares	1,329,153
Weighted Average Exercise Price, Outstanding at beginning of period | $ / shares	$ 6.24
Weighted Average remaining life, Outstanding at beginning of period	8 years 5 months 1 day
Weighted Average Intrinsic Value, Outstanding at beginning of period | $	$ 511,239
Options Outstanding, Granted | shares	3,300,141
Weighted Average Exercise Price, Granted | $ / shares	$ 4.85
Weighted Average remaining life, Granted	10 years
Weighted Average Intrinsic Value, Granted | $
Options Outstanding, Exercised | shares
Weighted Average Exercise Price, Exercised | $ / shares
Weighted Average Intrinsic Value, Exercised | $
Options Outstanding, Forfeited | shares
Weighted Average Exercise Price, Forfeited | $ / shares
Weighted Average Intrinsic Value, Forfeited | $
Options Outstanding, Expired | shares	(8,400)
Weighted Average Exercise Price, Expired | $ / shares
Weighted average intrinsic value, Expired | $
Options Outstanding at end of period | shares	4,620,894
Weighted Average Exercise Price, Outstanding at end of period | $ / shares	$ 5.25
Weighted Average remaining life, Outstanding at end of period	9 years 1 month 2 days
Weighted Average Intrinsic Value, Outstanding at end of period | $	$ 9,997,233
Options Exercisable | shares	1,209,730
Options Exercisable, Weighted Average Exercise Price | $ / shares	$ 6.48
Weighted Average Remaining Life, Exercisable end of period	7 years 9 months 29 days
Weighted Average Intrinsic Value, Exercisable end of period | $	$ 1,352,948

STOCKHOLDERS' EQUITY (Details 3

STOCKHOLDERS' EQUITY (Details 3) - Common Stock Purchase Warrants [Member]	6 Months Ended
	Dec. 31, 2021$ / sharesshares
Option Indexed to Issuer's Equity [Line Items]
Outstanding at beginning of period | shares	1,350,000
Weighted average exercise price, Outstanding at beginning of period | $ / shares	$ 1.30
Weighted Average remaining life, Outstanding	1 year 7 days
Granted | shares
Weighted average exercise price, Granted | $ / shares
Exercised | shares	(100,000)
Weighted average exercise price, Exercised | $ / shares	$ 1.30
Cancelled/Expired | shares
Weighted average exercise price, Expired | $ / shares
Outstanding at end of period | shares	1,250,000
Weighted average exercise price, Outstanding at end of period | $ / shares	$ 1.30
Weighted Average remaining life, Outstanding	6 months 10 days

STOCKHOLDERS' EQUITY (Details 4

STOCKHOLDERS' EQUITY (Details 4) - Warrant [Member] - Exercise Price Range 4 [Member]	6 Months Ended
	Dec. 31, 2021$ / sharesshares
Accumulated Other Comprehensive Income (Loss) [Line Items]
Exercise Prices	$ 1.30
Equivalent Shares Underlying Warrants Outstanding, Equivalent Shares | shares	1,250,000
Equivalent Shares Underlying Warrants Outstanding, Weighted Average Remaining Contractual Life (years)	6 months 10 days
Equivalent Shares Underlying Warrants Outstanding, Weighted Average Exercise Price	$ 1.30
Equivalent Shares Exercisable, Number Exercisable | shares	1,250,000
Equivalent Shares Exercisable, Weighted Average Exercise Price	$ 1.30

STOCKHOLDERS' EQUITY (Details 5

STOCKHOLDERS' EQUITY (Details 5) - Restricted Stock Units (RSUs) [Member]	6 Months Ended
	Dec. 31, 2021USD ($)$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding at beginning of period | shares	5,000
Weighted average exercise price, Outstanding at beginning of period | $ / shares	$ 6.15
Weighted Average remaining life, Outstanding	7 days
Weighted Average Intrinsic Value, Outstanding at Beginning of period | $
Granted | shares	36,266
Weighted average exercise price, Granted | $ / shares
Weighted Average Intrinsic Value, granted | $
Exercised | shares	(36,266)
Weighted average exercise price, Exercised | $ / shares
Weighted Average Intrinsic Value, exercised | $
Cancelled/Expired | shares
Weighted average exercise price, Expired | $ / shares
Weighted Average Intrinsic Value, cancelled/ expired | $
Outstanding at end of period | shares	5,000
Weighted average exercise price, Outstanding at end of period | $ / shares	$ 6.15
Weighted Average remaining life, Exercisable end of period	7 days
Weighted Average Intrinsic Value, Outstanding at end of period | $

STOCKHOLDERS' EQUITY (Details 6

STOCKHOLDERS' EQUITY (Details 6) - Restricted Stock Units (RSUs) [Member] - $ / shares	6 Months Ended
	Dec. 31, 2021	Jun. 30, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Units	5,000	5,000
Weighted Average remaining life, Outstanding	7 days
Exercise Price Range 5 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Grant Price	6.15
Stock Units	5,000
Weighted Average remaining life, Outstanding	7 days
Weight Average Issuance Price	$ 6.15

STOCKHOLDERS_ EQUITY (Details N

STOCKHOLDERS’ EQUITY (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2021	Dec. 31, 2020	Jul. 08, 2021	Jun. 30, 2021	Jul. 21, 2020	Feb. 06, 2014
Subsidiary, Sale of Stock [Line Items]
Preferred Stock, Shares Authorized	10,000,000		10,000,000			10,000,000
Preferred Stock, Par or Stated Value Per Share	$ 0.0001		$ 0.0001			$ 0.0001
Common stock, shares authorized	100,000,000		100,000,000			100,000,000
Common stock, par value	$ 0.0001		$ 0.0001			$ 0.0001
Common stock, shares issued	52,633,267		52,633,267			52,219,661
Common stock, shares outstanding	52,633,267		52,633,267			52,219,661
Obligation to purchase					$ 20,000,000
Purchase of shares					200,000
Exceed amount					$ 1,000,000
Purchase agreement description			limited to 12,016,457 shares of Common Stock, representing 19.99%
Number of shares issued	277,340		277,340
Common stock reserved for issuance	17,414		17,414			17,414
Stock based compensation	$ 2,043,292	$ 359,391	$ 4,771,267	$ 668,482
Unrecognized compensation cost	$ 8,571,250		$ 8,571,250
Number of shares issued options to purchase	60,000		60,000
Share-based Payment Arrangement, Option [Member]
Subsidiary, Sale of Stock [Line Items]
Options Granted			4,629,294
Options Exercisable	1,209,730		1,209,730
Employee Stock Option One [Member]
Subsidiary, Sale of Stock [Line Items]
Intrinsic value of stock option	$ 1,352,948		$ 1,352,948
2014 Equity Incentive Plan [Member]
Subsidiary, Sale of Stock [Line Items]
Common stock reserved for issuance								1,206,000
DanDrit Denmark [Member]
Subsidiary, Sale of Stock [Line Items]
Common stock, shares outstanding	167,639		167,639
Employees [Member] | N 2019 Equity Incentive Plan [Member]
Subsidiary, Sale of Stock [Line Items]
Options Granted	120,900	9,201	3,130,200	9,201
Options vesting period	3 years	3 years	3 years	3 years
Board Of Directors And Scientific Advisory Members [Member]
Subsidiary, Sale of Stock [Line Items]
Options Granted	36,727	63,435	63,462	87,631
Agreement and Plan of Merger (the "Acquisition Agreement") [Member] | Enochian Biopharma Inc. and Weird Science LLC [Member]
Subsidiary, Sale of Stock [Line Items]
Common shares contingently issuable	1,250,000		1,250,000
Common Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Number of shares issued	413,606	126,244	413,606	265,811
Black Scholes [Member]
Subsidiary, Sale of Stock [Line Items]
Number of option issued			21,979
Vesting for services			$ 17,500
Restricted Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Stock based compensation	$ 255,340	$ 7,860	258,331	$ 17,066
Lincoln Park [Member]
Subsidiary, Sale of Stock [Line Items]
Number of shares purchase			$ 3,048,339
Purchase Agreement [Member]
Subsidiary, Sale of Stock [Line Items]
Issued shares							139,567
Lincoln Parks [Member]
Subsidiary, Sale of Stock [Line Items]
Purchase of shares					125,000

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)	Nov. 15, 2019	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2021	Dec. 31, 2020
Net Investment Income [Line Items]
Research and development expenses		$ 2,144,085	$ 1,334,468	$ 5,150,328	$ 2,384,844
Milestone payments				1,500,000
Up-front payment	$ 10,000,000	75,000		150,000
Payment for expenditures	$ 760,000
Service Agreements [Member]
Net Investment Income [Line Items]
Issued for services amount				210,000
Consulting Agreement [Member] | G-Tech [Member]
Net Investment Income [Line Items]
Monthly consulting fee				25,000
Research and development expenses		75,000	$ 75,000	150,000	$ 125,000
Monthly research costs				144,500
Payment for scientific staffing resources		$ 433,500		$ 867,000

RELATED PARTY TRANSACTIONS (Det

RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)	3 Months Ended	6 Months Ended
	Dec. 31, 2021	Dec. 31, 2021
Related Party Transactions [Abstract]
Related party costs	$ 718,500	$ 3,537,000